CR8700A - Hormonas humanas de glicoproteinas superagonistas y sus usos - Google Patents

Hormonas humanas de glicoproteinas superagonistas y sus usos

Info

Publication number
CR8700A
CR8700A CR8700A CR8700A CR8700A CR 8700 A CR8700 A CR 8700A CR 8700 A CR8700 A CR 8700A CR 8700 A CR8700 A CR 8700A CR 8700 A CR8700 A CR 8700A
Authority
CR
Costa Rica
Prior art keywords
glicoproteins
superagonist
hormones
human hormones
human
Prior art date
Application number
CR8700A
Other languages
English (en)
Inventor
W Szkudlinski Mariusz
D Weintraub Bruce
Original Assignee
Trophogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trophogen Inc filed Critical Trophogen Inc
Publication of CR8700A publication Critical patent/CR8700A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rehabilitation Therapy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion proporciona los metodos mejorados para la formacion de imagenes, la terapia dirigida y la deteccion de diagnostico utilizando hormonas glucoproteicas modificadas que tiene actividad incrementada sobre las hormonas de tipo silvestre.
CR8700A 2004-03-31 2006-10-20 Hormonas humanas de glicoproteinas superagonistas y sus usos CR8700A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55770404P 2004-03-31 2004-03-31

Publications (1)

Publication Number Publication Date
CR8700A true CR8700A (es) 2007-07-19

Family

ID=35150595

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8700A CR8700A (es) 2004-03-31 2006-10-20 Hormonas humanas de glicoproteinas superagonistas y sus usos

Country Status (13)

Country Link
US (1) US20090214424A1 (es)
EP (1) EP1738174A2 (es)
JP (1) JP2007530974A (es)
KR (1) KR20070026493A (es)
CN (1) CN1965234A (es)
AU (1) AU2005233923A1 (es)
BR (1) BRPI0509469A (es)
CA (1) CA2561545A1 (es)
CR (1) CR8700A (es)
IL (1) IL178389A0 (es)
MX (1) MXPA06011290A (es)
RU (1) RU2006138235A (es)
WO (1) WO2005101000A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101246176B (zh) * 2007-02-13 2013-06-05 许洋 鳞状细胞癌抗原阴性宫颈癌血清蛋白质检测的质谱试剂及其制备方法
CN102372780A (zh) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用
CN102847151B (zh) * 2011-07-01 2014-08-13 天津金耀集团有限公司 含有巯乙基磺酸钠和糖皮质激素的吸入制剂及其制备方法
RU2668174C2 (ru) 2012-07-30 2018-09-26 Трофоген Инк. Суперагонисты гликопротеинового гормона длительного действия
KR20150041793A (ko) * 2012-08-21 2015-04-17 레프로스 쎄라피우틱스 아이엔씨. 트랜스-클로미펜 제형 및 그의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326467B1 (en) * 1989-02-23 2001-12-04 Colorado State University Research Foundation Hormone-recombinant toxin compounds and methods for using same
WO1991013090A1 (en) * 1990-03-02 1991-09-05 Diane Williams Improved chimeric toxins
JP3981413B2 (ja) * 1996-05-08 2007-09-26 アメリカ合衆国 糖タンパク質ホルモンスーパーアゴニスト
US6361992B1 (en) * 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
EP1816199A1 (en) * 1997-09-22 2007-08-08 University of Maryland at Baltimore Mutants of thyroid stimulating hormone and methods based thereon
EP1115866A1 (en) * 1998-09-22 2001-07-18 University of Maryland at Baltimore Cystine knot growth factor mutants

Also Published As

Publication number Publication date
EP1738174A2 (en) 2007-01-03
RU2006138235A (ru) 2008-05-10
WO2005101000A3 (en) 2006-11-23
MXPA06011290A (es) 2007-03-21
JP2007530974A (ja) 2007-11-01
BRPI0509469A (pt) 2007-09-11
CN1965234A (zh) 2007-05-16
IL178389A0 (en) 2007-02-11
CA2561545A1 (en) 2005-10-27
US20090214424A1 (en) 2009-08-27
AU2005233923A1 (en) 2005-10-27
KR20070026493A (ko) 2007-03-08
WO2005101000A2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
ECSP088508A (es) Antagonistas de neuropilina
DE60332355D1 (de) Hla-a24-restringiertes krebsantigenpeptid
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
ECSP077280A (es) Moduladores de quinasa de pirrolo-piridina
ECSP10010322A (es) Anticuerpos contra el virus de la influenza y métodos de uso de los mismos
CR20130335A (es) Anticuerpos anti-mesotelina e inmunoconjugados
BR112015020804A2 (pt) dispositivo fototerapeutico, método e uso
AR060978A1 (es) Anticuerpos e inmunoconjugados y sus usos
MX2009008926A (es) Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
CR10314A (es) Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina
CO2023014770A2 (es) Degradadores de cdk2 y sus usos
CR10734A (es) Anticuerpos e inmunoconjugados y sus usos
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
PA8678401A1 (es) Anticuerpos monoclonales anti-trkb y sus usos
CR20120449A (es) Formas de rifaximina y sus usos
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
ECSP099785A (es) Anticuerpos anti-notch1 nrr y sus métodos de uso
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
MX340972B (es) Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.
BRPI0719141A2 (pt) Sistema e método para gerar imagem de câncer de próstata, meio legível por computador, e, usos do sistema e de tomografia óptica difusa
GT200700096A (es) Compuestos de pirazolina
BRPI0515518A (pt) análogos de loxapina e métodos de usos dos mesmos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)